Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2006

Conditions
Asthma
Interventions
DRUG

Combivent® CFC MDI

DRUG

Albuterol HFA MDI

Trial Locations (27)

Unknown

620 South 20th Street, NHB 104, Birmingham

Cooper Green Hospital, Birmingham

Southern California Clinical Trials, Lakewood

Boehringer Ingelheim Investigational Site, Palmdale

Boehringer Ingelheim Investigational Site, Wheat Ridge

Norwalk Hospital, Norwalk

University of Miami School of Medicine, Miami

Boehringer Ingelheim Investigational Site, Panama City

Boehringer Ingelheim Investigational Site, Coeur d'Arlene

Boehringer Ingelheim Investigational Site, River Forest

Boehringer Ingelheim Investigational Site, Olathe

LSU MC-Sheveport, Shreveport

Boehringer Ingelheim Investigational Site, Auburn

Johns Hopkins Asthma & Allergy, Baltimore

Brigham & Women's Hospital, Boston

Boehringer Ingelheim Investigational Site, Berlin

Boehringer Ingelheim Investigational Site, Cherry Hill

North Shore University Hospital, Manhasset

NYU School of Medicine, New York

Division of Pulmonary & Critical Care Medicine, Durham

Wake Forest University, Center for Human Genomics, Winston-Salem

Penn State University, Hershey Medical Center, Hershey

Boehringer Ingelheim Investigational Site, Charleston

Spartanburg Medical Research, Spartanburg

Ben Taul General Hospital, Houston

University of Texas Health Center at Tyler, Tyler

University of Wisconsin Hospital, Madison

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY